NanoViricides (NNVC) Stock Price, News & Analysis

Company Overview

NanoViricides, Inc. is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses. Its lead influenza program has demonstrated promising results in animal models, supporting the potential for reduced viral loads and improved survival outcomes. NanoViricides also pursues combination strategies that leverage its nanoviricide constructs alongside standard antiviral agents to enhance efficacy and limit the emergence of resistance.

R&D activities are conducted primarily at the company’s facilities in Shelton, Connecticut, with supplemental collaborations through contract research organizations in the United States and abroad. NanoViricides maintains manufacturing partnerships to support scale-up of its nanomedicine formulations under current Good Manufacturing Practice (cGMP) guidelines. The company continually seeks strategic alliances and licensing opportunities to advance its technology across multiple viral indications and geographic markets.

Founded in 2005, NanoViricides operates under the leadership of its founder and Chief Executive Officer, Dr. Anil R. Diwan. The company’s management team draws on interdisciplinary expertise in virology, nanotechnology and pharmaceutical development. With a commitment to addressing unmet medical needs in infectious diseases, NanoViricides aims to progress its clinical candidates toward regulatory milestones and potential commercial adoption.

Key Stats

• Today's Range: $1.43 to $1.47
• 50-Day Range: $1.37 to $1.75
• 52-Week Range: $0.94 to $1.92
• Volume: 94,421 shs
• Average Volume: 233,703 shs
• Market Capitalization: $22.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NanoViricides Stock Analysis - MarketRank™

NanoViricides scored higher than 12% of companies evaluated by MarketBeat, and ranked 876th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NanoViricides.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NanoViricides is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NanoViricides is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NanoViricides has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.26% of the outstanding shares of NanoViricides have been sold short.

Short Interest Ratio / Days to Cover

NanoViricides has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NanoViricides has recently decreased by 50.06%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NanoViricides does not currently pay a dividend.

Dividend Growth

NanoViricides does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.26% of the outstanding shares of NanoViricides have been sold short.

Short Interest Ratio / Days to Cover

NanoViricides has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NanoViricides has recently decreased by 50.06%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.25

News Sentiment

NanoViricides has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for NanoViricides this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for NNVC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

19 people have added NanoViricides to their MarketBeat watchlist in the last 30 days. This is an increase of 280% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NanoViricides insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of NanoViricides is held by insiders.

Percentage Held by Institutions

Only 10.30% of the stock of NanoViricides is held by institutions.

NNVC Stock Analysis - Frequently Asked Questions

How have NNVC shares performed this year?

NanoViricides' stock was trading at $1.43 at the start of the year. Since then, NNVC stock has increased by 0.3% and is now trading at $1.4350.

How were NanoViricides' earnings last quarter?

NanoViricides, Inc. (NYSE:NNVC) released its earnings results on Friday, September, 27th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01.

When did NanoViricides' stock split?

NanoViricides shares reverse split before market open on Tuesday, September 24th 2019.The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are NanoViricides' major shareholders?

NanoViricides' top institutional investors include XTX Topco Ltd (0.13%).
View institutional ownership trends.

How do I buy shares of NanoViricides?

Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), NVIDIA (NVDA), Micron Technology (MU), Inovio Pharmaceuticals (INO), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 9/27/2024
• Today: 9/10/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NNVC
• CIK: 1379006
• Web: www.nanoviricides.com
• Phone: (203) 937-6137
• Fax: 203-859-5095
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -87.90%
• Return on Assets: -78.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.44
• Quick Ratio: 2.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 2.20

Miscellaneous

• Outstanding Shares: 16,072,000
• Free Float: 14,922,000
• Market Cap: $23.38 million
• Optionable: Optionable
• Beta: 1.15